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Background: Dinaciclib, a small-molecule, cyclin-dependent kinase inhibitor, inhibits cell cycle progression and
proliferation in various tumor cell lines in vitro. We conducted an open-label, dose-escalation study to determine
the safety, tolerability, and bioactivity of dinaciclib in adults with advanced malignancies.
Methods: Dinaciclib was administered starting at a dose of 0.33 mg/m2, as a 2-hour intravenous infusion once
weekly for 3 weeks (on days 1, 8, and 15 of a 28-day cycle), to determine the maximum administered dose (MAD),
dose-limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and safety and tolerability. Pharmacodynamics
of dinaciclib were assessed using an ex vivo phytohemagglutinin lymphocyte stimulation assay and
immunohistochemistry staining for retinoblastoma protein phosphorylation in skin biopsies. Evidence of antitumor
activity was assessed by sequential computed tomography imaging after every 2 treatment cycles.
Results: Forty-eight subjects with solid tumors were treated. The MAD was found to be 14 mg/m2 and the RP2D
was determined to be 12 mg/m2; DLTs at the MAD included orthostatic hypotension and elevated uric acid.
Forty-seven (98%) subjects reported adverse events (AEs) across all dose levels; the most common AEs were
nausea, anemia, decreased appetite, and fatigue. Dinaciclib administered at the RP2D significantly inhibited
lymphocyte proliferation, demonstrating a pharmacodynamic effect. Ten subjects treated at a variety of doses
achieved prolonged stable disease for at least 4 treatment cycles.
Conclusions: Dinaciclib administered every week for 3 weeks (on days 1, 8, and 15 of a 28-day cycle) was
generally safe and well tolerated. Initial bioactivity and observed disease stabilization support further evaluation
of dinaciclib as a treatment option for patients with advanced solid malignancies.
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Cyclin-dependent kinases (CDKs) are serine/threonine
kinases that regulate progression through the cell cycle
[1]. They exist in heterodimeric complexes with cyclins
and are activated at different stages of the cell cycle by
various cyclins. Eleven CDKs have been identified with
distinct functions in controlling the activation of the cell
cycle and progression from the G1 phase through mitosis
[2]. Phosphorylation of the retinoblastoma (Rb) family of
proteins is an important mechanism by which the CDKs
regulate cell cycle progression [3]. In addition to their
role in cell cycle progression, CDKs also play an import-
ant role in transcriptional regulation by phosphorylating
the carboxy-terminal domain of the large subunit of ribo-
nucleic acid polymerase II; CDK7/cyclin H and CDK9/
cyclin T have been shown to play important roles in tran-
scription initiation and elongation, respectively [4].
Dysregulation of the cell cycle plays an important
role in malignant transformation and the development
of resistance to chemotherapy [4]. Overexpression or
underexpression of the cyclins and CDKs that regulate
the cell cycle has been observed in a variety of tumors
and proliferative diseases, including melanoma [5], mul-
tiple myeloma [6], pituitary adenomas and carcinomas [7],
chronic lymphocytic leukemia (CLL) [8], and other solid
malignancies [9,10]. This has spurred interest in the
development of novel anticancer agents that target CDKs.
As anticancer treatments, CDK inhibitors have been
found not only to block cell cycle progression but also
to promote apoptosis, which leads to cell death. In par-
ticular, CDK inhibitors have shown high activity in cell
lines from nonproliferative cancers such as CLL and mul-
tiple myeloma due to their ability to induce apoptosis [11].
Dinaciclib (MK-7965, formerly SCH727965) is a novel,
potent, small-molecule inhibitor of CDK1, CDK2, CDK5,
and CDK9 with half maximal inhibitory concentration
(IC50) values in the 1 nM to 4 nM range, and inhibits
CDK4, CDK6, and CDK7 at IC50 values in the 60 nM to
100 nM range [12,13]. Dinaciclib was initially selected
from a compound screen in a mouse xenograft model,
using flavopiridol as the reference [12]. The maximum
tolerated dose, defined as the dose associated with 20%
weight loss, was 60 mg/kg for dinaciclib versus <10 mg/kg
for flavopiridol following once-daily administration for
7 days in nude mice. The dinaciclib minimum effective
dose, defined as >50% tumor growth inhibition, was
5 mg/kg versus 10 mg/kg for flavopiridol, yielding a
screening therapeutic index of >10 for dinaciclib and <1
for flavopiridol. Although not formally investigated, the
strong selectivity for CDKs—but not the closely related
serine/threonine kinases—suggests that dinaciclib may
target an activated CDK conformation not present in
serine/threonine kinases. In vitro, dinaciclib has been
shown to suppress phosphorylation of the Rb tumorsuppressor protein, to induce activation of caspase and
apoptosis, and to inhibit cell cycle progression and pro-
liferation in various tumor cell lines [5,12,14]. Promising
antitumor activity following treatment with dinaciclib
has also been demonstrated using in vivo mouse xenograft
models, with minimal toxic effects at active dose levels
[5,12,14,15], and tissue fragments of patient-derived xeno-
grafts grown in mice [5,12,14,15].
We conducted a phase 1 study with dinaciclib, adminis-
tered as a 2-hour intravenous (IV) infusion once every week
for 3 weeks followed by a 1-week recovery (28-day cycle),
in subjects with advanced malignancies. The primary
objectives of this study were to determine the safety,
tolerability, maximum administered dose (MAD), dose-
limiting toxicity (DLT), and recommended phase 2 dose
(RP2D) of dinaciclib, and to assess pharmacodynamic (PD)
effects using an ex vivo lymphocyte stimulation assay, Rb
protein phosphorylation, and 18 F-fluorodeoxyglucose posi-
tron emission tomography/computed tomography (FDG-
PET/CT).Methods
Study population
This was a nonrandomized, open-label, phase 1 trial
(ClinicalTrials.gov identifier #NCT00871663; http://
clinicaltrials.gov/ct2/show/NCT00871663; Protocol 04629)
of adult subjects (≥18 years) with histologically proven solid
tumors, non-Hodgkin’s lymphoma, or multiple myeloma
refractory to standard therapy or for which there is no
standard therapy. Subjects had Eastern Cooperative
Oncology Group (ECOG) performance statuses of 0, 1
or 2 and had to have adequate organ function and labora-
tory parameters. Subjects were excluded from the study if
they had symptomatic brain metastases or primary central
nervous system malignancy. Subjects must not have re-
ceived any radiation therapy within 4 weeks prior to the
start of treatment with dinaciclib, or have had a history
of radiation therapy to greater than 25% of the total bone
marrow. In addition, subjects could not have received pre-
vious treatment with an investigational drug or biologic or
hormonal therapy within 4 weeks of study treatment;
mitomycin, nitrosourea, nilutamide, or bicalutamide
within 6 weeks of study treatment; or cytochrome P450
3A4 inhibitors or inducers within 1 week of study treat-
ment. Known human immunodeficiency virus (HIV) and
HIV-related malignancy were also exclusion criteria.
The study was conducted in accordance with good clin-
ical practice and the Declaration of Helsinki concerning
written informed consent and the protection of rights of
human subjects. Before study initiation, the clinical study
protocol, any amendments, and the written informed con-
sent forms were reviewed and approved by an independ-
ent review board at each study site. Each subject had to
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study-related activities.
Study endpoints and treatment plan
The primary endpoints of the study were to determine
the safety, tolerability, MAD, DLT, and the RP2D of
dinaciclib, and to assess the PD effects of dinaciclib on
peripheral blood lymphocytes. Secondary endpoints in-
cluded determining the pharmacokinetic (PK) profile of
dinaciclib following a single dose and following the third
weekly dose, assessment of Rb protein phosphorylation
in subject skin biopsy samples, preliminary evaluation of
the antitumor activity of dinaciclib, and assessment of
tumor metabolic changes in response to dinaciclib treat-
ment via use of FDG-PET/CT.
Dinaciclib was administered as a 2-hour IV infusion
on days 1, 8, and 15 of a 28-day cycle. The 2-hour duration
of IV infusion was selected based on previous nonclinical
toxicity/toxicokinetic studies conducted in dogs that dem-
onstrated acute toxicity following IV push. Subjects con-
tinued on treatment until there was disease progression,
unacceptable toxicity, or the subject withdrew consent.
The trial employed an accelerated titration design [16]
starting at a dose of 0.33 mg/m2 (one-sixth of the highest
nontoxic dose in dogs). Routine antiemetic prophylaxis
was administered to patients receiving a dose of 7.11 mg/m2
and above, due to nausea and vomiting observed at lower
dose levels. Antiemetic prophylaxis consisted of a serotonin-
receptor antagonist (eg, ondansetron), with or without
dexamethasone, administered prior to treatment with
dinaciclib, and modifications were permitted as clinic-
ally indicated.
Toxicity, safety, and tolerability assessments
To determine the MAD of dinaciclib administered as a
2-hour IV infusion, an accelerated titration design was
used, whereby at least one subject was treated at each
dose level starting with 0.33 mg/m2; the dose was dou-
bled in sequential subjects until a DLT was observed or
a subject experienced grade 2 toxicity [16]. In the case
of an observed grade 2 toxicity, a second subject was
enrolled at the same dose level. If the second subject
also experienced a grade 2 toxicity, 2 additional subjects
were accrued at that dose level for a total of 4 subjects. In
the case of an observed DLT, additional subjects were
added to the cohort until either a second subject experi-
enced a DLT or 6 subjects were treated at that dose level.
If 2 or more subjects experienced a DLT at a given dose,
then 3 additional subjects were treated at the previous
lower dose, unless 6 subjects had already been treated
at that dose. Dose escalations beyond the 1.32-mg/m2
dose level were administered in increments of 40% in
cohorts of 3 subjects. Each subject was allocated to only
a single dose level of drug. Dose delay or modificationwas permitted based on laboratory and clinical assess-
ment performed on the day of treatment. The RP2D
was defined as the highest dose studied, without growth
factor support, for which the incidence of DLT was less
than 33% (ie, the dose level immediately lower than the
MAD), determined based on myeloma and NSCLC mouse
xenograft models, which showed complete tumor regres-
sion at a dose 33% of the MAD.
Dose-limiting toxicities were determined during the
first cycle for each dose level. A DLT was defined as any
grade 3 or 4 hematologic toxicity lasting for at least 1 week,
or as any grade 3 or 4 nonhematologic toxicity. Untreated
nausea and vomiting, fatigue, anorexia, anemia, alope-
cia, or local reactions were not included in the determin-
ation of DLTs and did not alter the escalation schedule,
unless inclusion was deemed necessary by the investigator
and sponsor. Normal alkaline phosphatase level (< grade 1)
at screening that rose to greater than or equal to grade 3;
grade 1 or 2 alkaline phosphatase level at screening that
rose to grade 4; grade 1 or 2 aspartate aminotransferase
(AST) and/or alanine aminotransferase (ALT) levels at
screening that doubled from baseline to become greater
than or equal to grade 3; and any other abnormal
nonhematology laboratory value greater than or equal
to grade 3 that required medical intervention to treat,
led to hospitalization, or persisted for at least 1 week
were also considered DLTs.
Safety and tolerability of dinaciclib were assessed based
on review of laboratory test results, electrocardiograms,
vital signs, physical examinations, and reported adverse
events (AEs). Any abnormal laboratory results that led
to hospitalization, resulted in a change in dosing, or were
medically significant were reported as AEs. Adverse events
were graded based on the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI
CTCAE version 3.0) and were coded using the Medical Dic-
tionary for Regulatory Activities (MedDRA version 13.0).
Pharmacodynamic and pharmacokinetic assessments
The antiproliferative activity of dinaciclib was assessed
ex vivo using whole blood samples obtained on days 1
and 15 of cycle 1 (predose and at 2, 3, 4, 6, and 8 hours
after the start of infusion), predose on day 8 of cycle 1,
and on day 22 of cycle 1. Whole blood isolated from
subjects was treated with phytohemagglutinin (PHA) to
stimulate cell division in lymphocytes. Following a brief
30-minute exposure to bromodeoxyuridine (BrdU), cells
were harvested and stained using an FITC-conjugated
antibody specific for BrdU, counterstained with propidium
iodide/RNase A, and analyzed using a FACSCalibur flow
cytometer. Approximately 35% to 40% of the CD45-
positive cells in the whole blood incorporate BrdU follow-
ing PHA stimulation under conditions defined in this
assay, signifying DNA synthesis and cell division. Any
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ment was classified as a responder to dinaciclib treatment.
To explore the relationship between exposure and bio-
activity of dinaciclib,%BrdU incorporation was correlated
with the amount of dinaciclib found in plasma samples
taken at the same time.
Skin punch biopsies (4 mm) were obtained before and
4 hours after treatment with dinaciclib, and fixed in 10%
buffered formalin for immunohistochemistry (IHC) ana-
lysis. The phosphorylation status of the Rb protein in
the proliferative layer of skin and in the proliferating cells at
the base of hair follicles was determined by IHC utilizing a
rabbit anti-phospho-Rb antibody diluted to 0.83 μg/mL or
0.67 μg/mL. Immunohistochemistry staining was scored
0 (no staining relative to background), 1+ (weak staining),
2+ (moderate staining), or 3+ (strong staining); H-score
was calculated as a measure of overall immunoreactivity
in a given sample, using the following formula: H-score =
(% of cells with 3+) × 3 + (% of cells with 2+) × 2 + (% of
cells with 1+) × 1. Subjects were to be categorized as re-
sponders if no degree of staining was detected with the
anti-phospho-Rb antibody.
Pharmacodynamic effects were further assessed by moni-
toring decreased metabolic activity following IV infusion
of dinaciclib using FDG-PET/CT scans, conducted within
14 days prior to the first dose of dinaciclib and on day
22 of cycle 1, unless treatment was delayed. Metabolic
activity data were obtained for research use only and
were not used for clinical management of subjects. A 30%
reduction in posttreatment standardized uptake value
(SUVmax), in up to 6 lesions prospectively identified at
the start of treatment as the most representative meta-
bolically active sites of disease, was used to determine
responders and nonresponders to dinaciclib treatment.
Dinaciclib plasma concentrations were analyzed on days
1 and 15 of cycle 1 prior to the start of infusion, and at
1 hour, 2 hours, 2 hours 15 minutes, 2 hours 30 minutes,
3 hours, 3 hours 30 minutes, 4 hours, 5 hours, 6 hours,
and 8 hours after the start of the infusion. Additional
blood samples for PK analysis were obtained on days 2
and 16 of cycle 1 (between 24 and 28 hours after the start
of the infusion), on day 8 of cycle 1, and on day 1 of cycle
2, prior to and 2 hours after the start of the infusion.
Plasma concentrations of dinaciclib were determined, as
previously described, using validated high performance
liquid chromatographic-tandem mass spectrometry (LC-
MS/MS) methods [17]. Briefly, plasma samples were
fortified with an internal standard (13C3)-dinaciclib in
1:1 ratio, loaded into a Water Oasis MCX Solid Phase
Extraction plate, washed with phosphoric acid/methanol,
and eluted with methanol/ammonium hydroxide. The
eluent was evaporated and the extract injected into a
LC-MS/MS. The retention time for dinaciclib and the
internal standard was 2.5 minutes and detection wasperformed using a Sciex API 5000 triple quadrupole
LC-MS/MS system with a turbo ion spray source. Key
pharmacokinetic parameters evaluated for dinaciclib in-
cluded maximum observed plasma concentration (Cmax),
time of maximum plasma concentration (Tmax), area
under the plasma concentration-time curve from time
zero to infinity (AUC(I)), terminal phase half-life (t½),
clearance (CL), volume of distribution (Vd), and accu-
mulation ratio (R).
Tumor response assessment
Antitumor activity of dinaciclib on solid tumors was
evaluated using CT or magnetic resonance imaging (MRI)
scans and Response Evaluation Criteria In Solid Tumors
(RECIST) guidelines [18]. Computed tomography or MRI
scans were obtained within 4 weeks prior to the start of
treatment with dinaciclib, and were repeated after every
2 cycles and at the poststudy assessment performed
4 weeks after the start of the last cycle.
Statistical analyses
Demographic and baseline variables for each subject
(including primary diagnosis) were tabulated and sum-
marized using descriptive statistics. No inferential ana-
lysis of safety data was planned; subjects reporting any
AEs, the occurrence of specific AEs, and discontinuation
due to AEs were summarized using descriptive statistics.
For%BrdU incorporation (PD primary endpoint), the re-
sponse rate and its 95% 2-sided exact confidence inter-
val (CI) were calculated if 6 or more responders were
observed among 10 subjects; a level at which the lower
limit of the 2-sided 95% exact CI was expected to be
greater than 25%, allowing inference with high confi-
dence that the metabolic inhibition rate was more than
25%. For each dose level, treatment effect on inhibition
of lymphocyte proliferation was evaluated by comparing
the pretreatment with the posttreatment%BrdU incorp-
oration on days 1 and 15 at specified posttreatment time
points (2, 3, 4, 6, and 8 hours after the start of the infu-
sion) using a paired t-test (in dose levels with sample
sizes ≥3). For secondary endpoints, subjects were classi-
fied as responders or nonresponders and the response
rate and its 95% CI were determined. Summary statistics
(means, standard deviations, coefficients of variation)
were calculated using noncompartmental methods with
the WinNonlin software (V5.2, Pharsight, NC) for the
concentration-versus-time data at each sampling time
and for derived PK parameters.
Results and discussion
Subject disposition and baseline characteristics
The study enrolled 52 subjects with histologically proven
solid tumors for whom there was no known standard
therapy or who had disease refractory to standard therapy.
Table 1 Baseline demographic and disease characteristics









Black or African American 13 (27)
Multiracial 1 (2)
Age, years




18–64 years 30 (63)
≥65 years 18 (38)












Breast, melanoma 3 each
Prostate, cholangiocarcinoma, adenoid cystic,
sarcoma, pancreatic, neuroendocrine
2 each
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were enrolled but did not meet protocol eligibility criteria
and were never treated, and one subject who was enrolled
did not receive any treatment because of an AE. However,
when screening data from these subjects were available
for a given measurement, these subjects were included in
the corresponding analysis. According to the trial design,
all subjects continued treatment until disease progression
or treatment discontinuation due to toxicity or at the
subject’s request; most trial discontinuations were due
to disease progression (28 [58%] subjects) and symp-
tomatic deterioration (8 [17%] subjects).
Table 1 summarizes subject demographics and baseline
disease characteristics. The majority of patients enrolled in
the study were white (33 [69%] subjects), male (27 [56%]
subjects), and younger than 65 years old (30 [63%] sub-
jects), with a mean age of 61.6 years. Most subjects had
colorectal cancer (15), followed by non–small cell lung
cancer (NSCLC, 5), ovarian cancer (4), breast cancer (3),
and melanoma (3). The study population had received a
median of 3 (range 0–16) chemotherapy regimens prior to
enrolling into the trial.
Toxicity, safety, and tolerability of dinaciclib
A total of 11 subjects were administered doses of dinaciclib
ranging from 0.33 to 2.59 mg/m2; there were 2 instances of
grade 2 toxicity at 1.32 mg/m2, but no DLTs were experi-
enced at any of these dose levels. Therefore, subsequent
doses were escalated in 40% increments from 1.85 mg/m2
up to the MAD that was reached at a dinaciclib dose of
14 mg/m2. Two subjects among the 5 treated at the
MAD experienced a DLT, one with orthostatic hypotension
and one with elevated uric acid (Table 2). A lower dose
of 12 mg/m2 was tested and was determined to be the
RP2D for dinaciclib administered as a 2-hour IV infusion
once a week for 3 weeks followed by a 1-week recovery
period. A total of 11 subjects were tested at the RP2D
dose; one subject experienced septic shock as a DLT.
Additional DLTs experienced with dinaciclib included
hypokalemia, hypocalcemia, and hypophosphatemia expe-
rienced by 1 of 8 subjects treated at the 3.63 mg/m2 dose
level, and deep vein thrombosis in 1 of 7 subjects treated
at the 7.11 mg/m2 dose level.
A total of 47 (98%) subjects reported treatment-
emergent adverse events (TEAEs; Table 3), and 35 (73%)
subjects experienced AEs possibly related to study drug.
The most frequently reported treatment-related AEs were
nausea (16 [33%] subjects), anemia (10 [21%] subjects),
neutropenia (8 [17%] subjects), vomiting (8 [17%] subjects),
and fatigue (7 [15%] subjects). At the RP2D (12 mg/m2),
the most common treatment-related AEs reported by
at least 3 (>25%) of the 11 subjects treated at this dose
level were anemia (5 [45%]), neutropenia (4 [36%]), fa-
tigue (4 [36%]), nausea (3 [27%]), vomiting (3 [27%]),asthenia (3 [27%]), hyperuricemia (3 [27%]), and pyrexia
(3 [27%]). Sixteen (33%) subjects experienced grade 3 or
4 treatment-related AEs, with neutropenia (5 [10%] sub-
jects) and hyperuricemia (3 [6%] subjects) being the most
common. Serious AEs (SAEs) were reported in 17 (33%)
subjects; the most common SAEs were deep vein throm-
bosis, sepsis, and anemia, each occurring in 3 (6%) sub-
jects. Not all SAEs qualified as DLTs. No discernible
trend regarding tumor type and toxicity was identified
(Additional file 1: Table S1).






DLT in cycle 1
DLT
0.33 1 0 None
0.66 1 0 None
1.32 1 0 None
1.85 4 0 None
2.59 4 0 None
3.63 8 1 Hypokalemia, hypocalcemia,
hypophosphatemia
5.08 3 0 None
7.11 7 1 Deep vein thrombosis
10 3 0 None
12 11 1 Septic shock
14 5 2 Orthostatic hypotension (1),
elevated uric acid (1)
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this study. The most common reason for death was
disease progression (7 [13%] subjects) considered to be
unlikely related to study treatment. Deaths due to AEs
occurred in 4 (8%) subjects: one subject assigned to the
7.11-mg/m2 dose was never treated and died due to aspir-
ation; one subject who received the 7.11-mg/m2 infusion
dose died of cardiac arrest; one subject treated with the
14-mg/m2 infusion died of bowel perforations; and an-
other subject also treated at the 14-mg/m2 dose level
died of unknown cause. All 4 AEs leading to death were
deemed unlikely related to dinaciclib treatment by the
investigator. A total of 6 (13%) subjects reported AEs
leading to discontinuation of treatment, but in 4 of the
6 subjects, AEs leading to discontinuation were consid-
ered unlikely related to dinaciclib.
Pharmacodynamics and pharmacokinetics of dinaciclib
Lymphocyte proliferation (PHA-stimulated%BrdU uptake)
data were available from 46 of the 48 treated subjects.
Following treatment at the RP2D of 12 mg/m2, lympho-
cyte proliferation was generally inhibited compared with
proliferation levels observed pretreatment, although there
was some variability (Table 4). The inhibition of ex vivo
PHA-stimulated lymphocyte proliferation correlated with
the observed plasma concentrations from 46 subjects
(Figure 1A). The majority of samples had BrdU incorpor-
ation of less than 5% at plasma concentration of 100 ng/mL;
BrdU incorporation was completely inhibited at plasma
concentration >200 ng/mL. Complete inhibition of BrdU
uptake (relative to baseline) was achieved at dinaciclib
plasma concentrations greater than 100 ng/mL at about
2 hours after the start of IV infusion with dinaciclibdoses of approximately 5.08 mg/m2 and greater. Seven
subjects were evaluable for BrdU response rate at the
RP2D, and all 7 subjects were classified as responders
(BrdU response rate: 100%; 2-sided 95% CI: 59%, 100%).
Additionally, 10 of the 11 subjects treated with dinaciclib
at the RP2D had both pretreatment and cycle 1 day 22
SUVmax data, and were therefore evaluable for response
by PET/CT analysis. One subject at the RP2D was classified
as a PET/CT responder with the best SUVmax decrease be-
ing greater than 30% (Figure 1B); the PET/CT response
rate at the RP2D is 10.0% based on the 10 evaluable sub-
jects (2-sided 95% CI: 0.3%, 44.5%).
Analysis of subject skin biopsy samples demonstrated
pretreatment phospho-Rb staining. Mean IHC scores were
calculated before and after treatment for the 11 subjects
who were treated at the RP2D of 12 mg/m2. Before
dinaciclib treatment, these subjects had a mean H score
of 18.55; following treatment, the overall H score de-
creased to 17.64. Therefore, as no subjects demonstrated
complete loss of phospho-Rb staining following treatment
with dinaciclib, no subjects were deemed to have achieved
a response based on phospho-Rb staining, as defined in
the study protocol.
Of the 48 treated subjects, 47 subjects were evaluable
for the PK analysis; one subject who received IV infusion
for less than 1 hour—resulting in less than 3.63 mg/m2
dose of dinaciclib on day 1 of cycle 1—and had no
concentration-versus-time data on day 15 of cycle 1 was
excluded from the analysis. Following 2-hour IV adminis-
tration of dinaciclib, Cmax was observed at approximately
2 hours after the initiation of the infusion, and dinaciclib
exhibited rapid distribution and elimination phases after
the end of an infusion (Figure 2A). Terminal half-life
values ranged from 1.5 to 3.6 hours following IV adminis-
tration of dinaciclib, and CL appeared to be dose inde-
pendent. Dose-related increases in exposure to dinaciclib
were observed as doses increased from 0.33 to 14 mg/m2.
Exposure to dinaciclib was similar on days 1 and 15 after
once-weekly dosing, with a mean AUC(l) ratio (day 15 to
day 1) of 1.04 (Figure 2B). Plasma concentrations at the
end of each 2-hour infusion (on days 1, 8, and 15 of
cycle 1 and on day 1 of cycle 2) were also similar within
each subject (Figure 2C). These data suggest that dinaciclib
does not accumulate in plasma and pharmacokinetics
do not appear to be time dependent over the time course
evaluated in this study. Pharmacokinetic parameter means
at each dose level, assessed on day 1 and day 15, are
available as supplemental information (Additional file 2:
Table S2).
Tumor response
There were no observed complete or partial responses
(CR or PR) based on RECIST guidelines in subjects with
solid tumors following treatment with dinaciclib. Ten

















All grades Grade 3–4 All grades Grade 3–4 All grades Grade 3–4 All grades Grade 3–4 A rades Grade 3–4 All grades Grade 3–4
Subjects with any AE 47 (98) 29 (60) 21 (95) 11 (50) 7 (100) 4 (57) 3 (100) 1 (33) 100) 8 (73) 5 (100) 5 (100)
Anemia 19 (40) 5 (10) 8 (36) 1 (5) 3 (43) 2 (29) 0 0 55) 1 (9) 2 (40) 1 (20)
Nausea 19 (40) 1 (2) 6 (27) 0 5 (71) 0 1 (33) 0 27) 0 4 (80) 1 (20)
Fatigue 14 (29) 2 (4) 7 (32) 2 (9) 3 (43) 0 0 0 36) 0 0 0
Decreased appetite 14 (29) 0 9 (41) 0 2 (29) 0 0 0 18) 0 1 (20) 0
Urinary tract infection 12 (25) 0 5 (23) 0 2 (29) 0 1 (33) 0 36) 0 0 0
Asthenia 11 (23) 3 (6) 4 (18) 2 (9) 2 (29) 0 0 0 36) 0 1 (20) 1 (20)
Back pain 11 (23) 3 (6) 8 (36) 3 (14) 1 (14) 0 0 0 (9) 0 1 (20) 0
Vomiting 11 (23) 2 (4) 2 (9) 1 (5) 2 (29) 1 (14) 2 (67) 0 27) 0 2 (40) 1 (20)
Constipation 11 (23) 0 5 (23) 0 1 (14) 0 2 (67) 0 18) 0 1 (20) 0
Hyperbilirubinemia 9 (19) 5 (10) 5 (23) 3 (14) 0 0 0 0 27) 1(9) 2 (40) 1 (20)
Dehydration 9 (19) 0 8 (36) 0 1 (14) 0 0 0 0 3 (60) 0
Neutropenia 8 (17) 5 (10) 0 0 0 0 1 (33) 1 (33) 36) 2 (18) 3 (60) 2 (40)
Abdominal pain 8 (17) 2 (4) 4 (18) 1 (5) 3 (43) 1 (14) 1 (33) 0 0 0 0
Increased AST 8 (17) 2 (4) 3 (14) 1 (5) 0 0 0 0 36) 1 (9) 1 (20) 0
Increased ALP 8 (17) 2 (4) 3 (14) 1 (5) 0 0 0 0 36) 0 1 (20) 1 (20)
Pyrexia 8 (17) 0 3 (14) 0 1 (14) 0 0 0 36) 0 0 0
Hyperglycemia 7 (15) 4 (8) 1 (5) 0 0 0 1 (33) 1 (33) 36) 2 (18) 1 (20) 1 (20)
Dyspnea 7 (15) 3 (6) 3 (14) 1 (5) 3 (43) 1 (14) 0 0 0 1 (20) 1 (20)
Peripheral edema 7 (15) 0 3 (14) 0 1 (14) 0 0 0 27) 0 0 0
Hypophosphatemia 6 (13) 5 (10) 4 (18) 3 (14) 0 0 0 0 18) 2 (18) 0 0
Hypokalemia 6 (13) 2 (4) 2 (9) 1 (5) 1 (14) 0 1 (33) 0 18) 1 (9) 0 0
Increased ALT 6 (13) 1 (9) 3 (14) 1 (5) 0 0 0 0 27) 0 0 0
Diarrhea 6 (13) 0 3 (14) 0 1 (14) 0 1 (33) 0 (9) 0 0 0
Flatulence 6 (13) 0 3 (14) 0 2 (29) 0 0 0 (9) 0 0 0













































Table 3 TEAE’s occurring in ≥10% of subjects (Continued)
Dizziness 5 (10) 1(9) 0 0 3 (43) 0 0 0 1 (9) 0 1 (20) 1 (20)
Abdominal distension 5 (10) 0 3 (14) 0 1 (14) 0 0 0 1 (9) 0 0 0
Weight decreased 5 (10) 0 4 (18) 0 1 (14) 0 0 0 0 0 0 0
Cough 5 (10) 0 3 (14) 0 0 0 0 0 2 (18) 0 0 0
ALP = alkaline phosphatase.



















Table 4 Differences in mean percent BrdU uptake in ex vivo lymphocyte assays in subjects treated at RP2D of
dinaciclib 12 mg/m2
Time points Number of
patients
Mean percent difference in BrdU uptake
(95% CI)
Standard error Degrees of
freedom
t P value
Day 1 Predose – 2 hours 7 10.72 (4.69, 16.75) 2.46 6 4.35 0.005
Predose – 3 hours 7 9.28 (1.44, 17.13) 3.21 6 2.89 0.028
Predose – 4 hours 7 6.05 (−4.03, 16.12) 4.12 6 1.47 0.192
Predose – 6 hours 7 10.16 (3.89, 16.43) 2.56 6 3.96 0.007
Predose – 8 hours 6 8.76 (2.87, 14.65) 2.29 5 3.82 0.012
Day 15 Predose – 2 hours 7 14.82 (6.02, 23.61) 3.59 6 4.12 0.006
Predose – 3 hours 7 12.95 (2.01, 23.89) 4.47 6 2.90 0.028
Predose – 4 hours 7 5.47 (−4.17, 15.12) 3.94 6 1.39 0.214
Predose – 6 hours 6 15.90 (7.69, 24.11) 3.19 5 4.98 0.004
Predose – 8 hours 5 16.48 (5.63, 27.34) 3.91 4 4.21 0.014
BrdU = bromodeoxyuridine; PHA = phytohemagglutinin; RP2D = recommended phase 2 dose.
Results of paired t-tests showing the difference in mean percent BrdU uptake between predose and postdose ex vivo PHA lymphocyte stimulation assays.
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http://www.translational-medicine.com/content/11/1/259patients achieved stable disease (SD) through at least
4 cycles of treatment with dinaciclib, including 2 subjects
with NSCLC and 2 subjects with adenoid cystic carcinoma
(Table 5). One subject, with sarcoma, demonstrated pro-
longed SD through 12 treatment cycles.
In this study, the CDK inhibitor dinaciclib was adminis-
tered once weekly for 3 weeks followed by a 1-week recov-
ery period (28-day cycle) and had an acceptable safety
and tolerability profile for subjects with solid tumors.
The MAD for dinaciclib, administered at a 2-hour IV
infusion, was 14 mg/m2, and the DLTs experienced at
this dose level were orthostatic hypotension and elevated
uric acid. Hypotension may be associated with cytokine
release syndrome, which has been observed in patients
with hematologic malignancies and advanced solid tumors
treated with the CDK inhibitor flavopiridol, and has also
been identified as a DLT [19,20]. The most frequently
reported treatment-related AEs at all dose levels tested
were nausea and anemia, and 16 subjects experienced
grade 3 or 4 treatment-related AEs. Anemia, neutropenia,
and fatigue were the most common AEs related to study
drug reported at the RP2D of 12 mg/m2. The most fre-
quent SAEs among the 17 subjects who reported experi-
encing SAEs were deep vein thrombosis, sepsis, and
anemia. Adverse events led to the discontinuation of
treatment in 6 subjects and 4 subjects died due to AEs
that were deemed unrelated to dinaciclib.
Dinaciclib effectively inhibited peripheral blood lympho-
cyte proliferation, as measured by an ex vivo lymphocyte
stimulation assay, demonstrating PD activity when ad-
ministered at the RP2D (12 mg/m2) as a 2-hour IV infu-
sion. One mechanism by which CDK1 and CDK2 may
regulate the cell cycle is via phosphorylation of the Rb
tumor suppressor family of proteins [4]. In our study,treatment with dinaciclib did not result in substantial
decreases in the phosphorylation of the Rb protein in skin
biopsies, indicating that no subject had a PD response
to dinaciclib treatment based on the protocol-specified
criteria that required complete suppression of Rb phos-
phorylation. It is unlikely that the lack of an observed
PD effect using phospho-Rb staining of skin biopsies was
due to a limited effect of dinaciclib activity in inhibiting
the cell cycle, since dinaciclib treatment inhibited ex vivo
lymphocyte proliferation. In preclinical studies, IHC
staining of mouse skin biopsies looking at Rb phosphoryl-
ation at serine 807 and serine 811 demonstrated strong
pretreatment Rb phosphorylation followed by a time-
dependent loss of Rb phosphorylation, with a partial
loss at 2 hours post treatment and complete loss of Rb
phosphorylation at 4 hours post treatment [12,21]. The
lack of inhibition of phospho-Rb observed in our trial
may be due to the timing of the posttreatment skin
biopsy, as the nonclinical data from mice clearly showed
a time-dependent effect. Skin biopsies were obtained
4 hours post treatment, on the basis of mouse data, and
this may not be the optimal time point in patients.
Our trial enrolled subjects with a variety of solid tumors
who were heavily pretreated, as is typical in a phase 1
study population. Early PET/CT scan analysis, as a bio-
marker for SD, did not show any correlation between
tumor metabolic changes and treatment with dinaciclib.
Analysis of tumor response using RECIST criteria also
showed no objective responses (CR or PR) among the
subjects in this study. However, at least 10 subjects
achieved prolonged SD for at least 4 cycles of treatment,
with one subject demonstrating prolonged SD while re-
ceiving treatment for 12 cycles. Therefore, treatment with
dinaciclib may have the ability to delay disease progression
Figure 1 Pharmacodynamic relationships following treatment with
dinaciclib. Relationship between percentage of bromodeoxyuridine
uptake (relative to baseline) and dinaciclib plasma concentration (A), and
best percentage change in maximum standard uptake value (SUVmax)
determined by PET/CT scan (B) for subjects administered 0.33 to
14.0 mg/m2 doses of dinaciclib.
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small sample size of 48 treated subjects, no clear correl-
ation was observed between day 1/day 15 ex vivo lympho-
cyte proliferation inhibition (measured by BrdU uptake)
and day 22 PET/CT analysis SUVmax, or between day 22
PET/CT response (SUVmax decrease greater than 30%)
and the duration of SD. The lack of a correlation could be
due to the great heterogeneity among subjects’ baseline
characteristics in terms of tumor types, disease stage,
and the number of prior chemotherapy regimens. Alter-
natively, lower concentration and/or shorter duration of
drug exposure in the tumors compared with blood may
have accounted for the lack of correlation observed in
the study.
Several CDK inhibitors have been evaluated in phase 1
clinical trials, but none has demonstrated significant mono-
therapy activity in solid tumor patients, despite strong
preclinical data to support their use. The lack of correl-
ation of antitumor activity observed in vitro and in vivo,in this and other studies, may be affected by dosing
schedules and/or drug exposure. The pan-CDK inhibi-
tor flavopiridol was originally studied in 3 phase 1 trials
using 2 different schedules. No objective responses were
observed in a trial of 55 patients using a 1-hour daily infu-
sion for 5 days, 3 days, or 1 day in a 21-day cycle [22].
However, two trials evaluated flavopiridol with a 72-hour
continuous infusion given every 2 weeks, and this sched-
ule resulted in one PR in a patient with renal cancer in a
study of 76 patients, and one CR in a patient with gastric
cancer in a trial of 38 patients [23,24]. The CDK1, CDK2,
and CDK4 inhibitor PHA793887 did not show any object-
ive responses in a first-in-human study in solid tumor
patients [25], whereas one PR was observed with the CDK1,
CDK2, CDK4, CDK5, and CDK9 inhibitor AT7519 in a
patient with metastatic NSCLC [26]. Orally bioavailable
CDK inhibitors include the CDK1 and CDK2 inhibitor
AZD5438, the CDK1, CDK2, CDK7, and CDK9 inhibi-
tor seliciclib (CYC202; R-roscovitine), and the CDK4
and CDK6 inhibitor PD0332991. Phase 1 trials of these
agents report one PR in a patient with testicular cancer
among 33 patients treated with PD0332991 [27], and one
PR in a patient with hepatocellular carcinoma among
56 patients treated with seliciclib [28]. No responses
were observed in 3 phase 1 trials of AZD5438 [29] or
in a separate trial of seliciclib [30]. The identification
of biomarkers may help to stratify patients into specific
groups to determine the predictive response to CDK
inhibitors. Preclinical and phase 2 studies have associated
elevated expression of Rb protein, luminal ER subtype,
and reduced P16 expression with sensitivity to PD033299,
a selective inhibitor of CDK4/6 [31-33]. CDK4/CDK6
inhibitors shut down Rb phosphorylation; therefore, re-
sponses are precluded in tumor cells that lack Rb. In
contrast, to our knowledge, a clear predictive biomarker
profile for broad CDK inhibitors has not been identified.
The development of flavopiridol was marked by dose-
limiting diarrhea in both 72-hour continuous infusion
trials [23,24], and by dose-limiting neutropenia using the
daily 1-hour infusion schedule [22]. Several newer CDK
inhibitors, such as PD0332991, have also resulted in DLTs
of neutropenia [34]. Neutropenia as a DLT has been seen
with dinaciclib using higher doses (up to 57 mg/m2) on a
once-every-21-days dosing schedule [35]. Dose-limiting
toxicities with seliciclib, administered orally twice daily
for 7 days of a 21-day schedule, were similar to those
observed with dinaciclib using the once-weekly dosing
schedule, including hypokalemia, hyponatremia, elevated
gamma-glutamyl transferase, hyperglycemia, and vascu-
litic rash (myelosuppression was not observed as a DLT
with seliciclib) [30]. The first-in-human trial of PHA793887
administered as a 1-hour infusion on days 1, 8, and 15 in a
4-week cycle resulted in a patient with fatal hepatorenal
failure at the third dose level of 44 mg/m2 and a patient
Figure 2 Pharmacokinetics of dinaciclib following 2-hour infusion at different doses. Mean dinaciclib concentration-time profiles following
2-hour IV infusion on day 1 of cycle 1 (A), comparison of individual AUC(I) on days 1 and 15 of cycle 1 (B), and dinaciclib plasma concentrations
at the end of each 2-hour infusion (C) (on days 1, 8, and 15 of cycle 1 and on day 1 of cycle 2) for subjects administered dinaciclib at 0.33 mg/m2 to
14.0 mg/m2. For AUC(l), lines connect day 1 and day 15 values for subjects with data on both days.
Nemunaitis et al. Journal of Translational Medicine 2013, 11:259 Page 11 of 14
http://www.translational-medicine.com/content/11/1/259with grade 4 hepatic failure at the next dose level of
66 mg/m2, which led the sponsor to discontinue further
development of this agent [25]. Development of AZD5438
was also discontinued due to high variability and unpre-
dictable drug exposure combined with a lack of objectiveresponses [29]. Interestingly AZD5438 was studied first in
healthy volunteers with DLT of nausea and vomiting with
a single dose of 160 mg [36]; similar AZD5438 exposures
(40 mg four times a day) were not tolerated using various
continuous daily dosing schedules in the phase 1 trial in
Table 5 Patients with stable disease (RECIST) for at least














2902 NSCLC 0.66 16 SD 6
2910 Pseudomyxoma
peritonei
2.59 3 SD 9
2913 Prostate cancer 3.63 2 SD 4
2920 Melanoma 3.63 3 SD 10
2926 Sarcoma 7.11 2 SD 12
2928 Gastrointestinal
stromal tumor
7.11 2 SD 10
2931 Esophageal
carcinoma
7.11 3 SD 11
2932 Adenoid cyst
carcinoma
7.11 0 SD 5
2937 Adenoid cyst
carcinoma
14.0 3 SD 8
2945 NSCLC 12.0 4 SD 4
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of AZD5438 and PHA793887 are off-target effects or if
they are due to CDK inhibition.Conclusions
Several preliminary reports from phase 1 clinical trials have
demonstrated enhanced antitumor activity when CDK
inhibitors are combined with cytotoxic agents, in patients
with both advanced solid tumors [37,38] and estrogen
receptor-positive/human epidermal growth factor receptor
2-negative (ER+/HER2–) advanced breast cancer [39]. Ini-
tial results from an ongoing phase 2 trial examining the
combination of PD-0332991 and letrozole in ER+/HER2–
breast cancer patients showed significant improvements
in progression-free survival, as well as higher response
and clinical benefit rates with the combination compared
with letrozole alone [31]. Preclinical studies using tumor
cell lines have also shown promising results when CDK
inhibitors have been used in combination with other
targeted therapies, such as histone deacetylase inhibitors
(MS-275 and vorinostat) [40,41] and AKT inhibitors [42].
In early phase clinical trials, dinaciclib has also shown
encouraging results as monotherapy in CLL at the RP2D,
indicating dinaciclib may also be effective in some hema-
tologic malignancies. Other CDK inhibitors (eg, SNA-032)
have not demonstrated similar efficacy in subjects with
CLL [43]. These results suggest that dinaciclib combin-
ation strategies may be especially promising in solid tumors,
and dinaciclib as monotherapy or in combination may
also be effective in hematologic malignancies.Additional files
Additional file 1: Table S1. Mean pharmacokinetic parameters at each
dose level.
Additional file 2: Table S2. Patients with serious adverse events
regardless of causality and according to diagnosis at study entry.
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